Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$44.63 USD
+0.18 (0.40%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $44.62 -0.01 (-0.02%) 6:26 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Brokerage Reports
Tandem Diabetes Care, Inc. [TNDM]
Reports for Purchase
Showing records 161 - 180 ( 244 total )
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Guidance and Margins Much Better Than Expected, Paving a Path Toward Profitability; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Survey of Diabetes Educators Very Positive for DXCM''s Growth Outlook; Suggests Recent Concerns Misplaced; Reiterate OUTPERFORM on DXCM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Proprietary Survey of Diabetes Educators Suggests Patients Prefer Tandem''s Insulin Pumps; Reiterate OUTPERFORM on TNDM shares
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Pre-Announces In Line 4Q15 And Initial 2016 Revenue Guidance; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
MedTech 2016 Outlook: Risk/Reward Looks Attractive
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Positive (Albeit Temporary) Implications of a 2-Year Suspension of the Medical Device Tax
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Impressive Q3 Results, Price Target to $14.75, Reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
The Calm Before The Storm; Expecting Sales To Significantly Accelerate in 4Q and Beyond; Reiterate
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Feltl Insulin Pump Project: Historical survey of -5,700 users, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Insulin Pump Project: Historical survey of ~5,700 users, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
T:slim G4 Receives FDA Approval; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Conference Call Takeaways Following t:slim G4 Approval; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Medical Devices - Key Takeaways from the Wedbush PacGrow Healthcare Conference
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Key Takeaways from the Wedbush PacGrow Healthcare Conference
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Q2 beats, t:flex guidance raised, pipeline on track, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Insulin Pump Project: Historical survey of ~5,500 users, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Rapid Adoption of Tandem''s Insulin Pump Continues Unfazed by Competition; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.